NASDAQ:CNMD - CONMED Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$81.32 +1.31 (+1.64 %)
(As of 04/25/2019 04:00 PM ET)
Previous Close$80.01
Today's Range$80.19 - $85.91
52-Week Range$56.90 - $85.91
Volume793,607 shs
Average Volume314,071 shs
Market Capitalization$2.30 billion
P/E Ratio37.30
Dividend Yield1.00%
Beta0.67
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. It offers orthopedic surgery products under Hall, CONMED Linvatec, Concept, and Shutt brands. The company also offers general surgery product in the areas of advanced surgical comprising clinical insufflation system; electrosurgical products; endomechanical products comprising instruments, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors; and VCARE uterine manipulator for enhancing the efficiency of laparoscopic hysterectomies and other gynecologic laparoscopic procedures. In addition, it offers endoscopic technologies offering, including diagnostic and therapeutic products for use in gastroenterology procedures; cardiology and critical care products cover a line of vital signs, cardiac monitoring, and patient care products, including ECG electrodes and accessories, cardiac defibrillation and pacing pads, and suction instruments and tubing; and physician's office electrosurgical product used by dermatologists. The company markets its products directly to surgeons, hospitals, surgery centers, group purchasing organizations, integrated delivery networks, and other customers, as well as through medical specialty distributors. CONMED Corporation was founded in 1970 and is headquartered in Utica, New York.

Receive CNMD News and Ratings via Email

Sign-up to receive the latest news and ratings for CNMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:CNMD
CUSIP20741010
Phone315-797-8375

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$859.63 million
Cash Flow$4.4608 per share
Book Value$23.54 per share

Profitability

Net Income$40.85 million

Miscellaneous

Employees3,100
Market Cap$2.30 billion
Next Earnings Date8/7/2019 (Estimated)
OptionableOptionable

CONMED (NASDAQ:CNMD) Frequently Asked Questions

What is CONMED's stock symbol?

CONMED trades on the NASDAQ under the ticker symbol "CNMD."

How often does CONMED pay dividends? What is the dividend yield for CONMED?

CONMED announced a quarterly dividend on Tuesday, February 26th. Stockholders of record on Friday, March 15th will be given a dividend of $0.20 per share on Friday, April 5th. This represents a $0.80 annualized dividend and a dividend yield of 0.98%. The ex-dividend date is Thursday, March 14th. View CONMED's Dividend History.

How were CONMED's earnings last quarter?

CONMED Co. (NASDAQ:CNMD) posted its earnings results on Wednesday, April, 24th. The medical technology company reported $0.57 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.54 by $0.03. The medical technology company had revenue of $218.38 million for the quarter, compared to the consensus estimate of $213.95 million. CONMED had a net margin of 4.75% and a return on equity of 9.65%. The business's quarterly revenue was up 8.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.53 earnings per share. View CONMED's Earnings History.

When is CONMED's next earnings date?

CONMED is scheduled to release their next quarterly earnings announcement on Wednesday, August 7th 2019. View Earnings Estimates for CONMED.

What guidance has CONMED issued on next quarter's earnings?

CONMED issued an update on its FY19 earnings guidance on Wednesday, April, 24th. The company provided earnings per share guidance of $2.47-2.52 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.45. The company issued revenue guidance of $937.4-946.0 million, compared to the consensus revenue estimate of $944.24 million.CONMED also updated its FY 2019 guidance to $2.47-2.52 EPS.

What price target have analysts set for CNMD?

4 Wall Street analysts have issued 12 month price targets for CONMED's stock. Their forecasts range from $81.00 to $95.00. On average, they expect CONMED's stock price to reach $90.50 in the next year. This suggests a possible upside of 11.3% from the stock's current price. View Analyst Price Targets for CONMED.

What is the consensus analysts' recommendation for CONMED?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CONMED.

What are Wall Street analysts saying about CONMED stock?

Here are some recent quotes from research analysts about CONMED stock:
  • 1. According to Zacks Investment Research, "CONMED outperformed the industry in a year’s time. The company’s core units — Orthopedic Surgery and General Surgery — continue to boost the topline. Of the most unique products under General Surgery, the Anchor Tissue Retrieval bag deserves a mention. Solid international sales growth in recent times is a positive. Management is confident of the company’s broad product portfolio as well. It expects the ongoing buyout of Buffalo Filter to boost CONMED’s General Surgery portfolio. A strong 2019 guidance buoy optimism in the stock. On the flip side, contraction in the company's gross and operating margins in recent times is worrisome. CONMED operates in a highly competitive environment, especially with respect to the General Surgery business. The company’s high long-term debt is a concern. The stock looks overvalued at the moment." (4/15/2019)
  • 2. Needham & Company LLC analysts commented, "CNMD’s 4Q18 revenue beat consensus while its EPS was in line with consensus. Management provided 2019 revenue and EPS guidance that were both above consensus. Revenue growth improved to 10.8% CC (or ~9.3% CC after adjusting for an extra selling day) in 4Q18 from 8.1% CC in 3Q18 despite a more difficult comp. CNMD’s revenue grew 8.4% in 2018, which is ~400 bps above the mid-point of its original 4-5% guidance. We believe that the 2019 revenue guidance is similarly conservative and note that management indicated that they intend to allow any revenue upside to fall through to the bottom line rather than reinvesting this as in 2018. Given this, we reiterate our Buy rating." (1/23/2019)

Has CONMED been receiving favorable news coverage?

News articles about CNMD stock have trended somewhat positive on Thursday, according to InfoTrie. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. CONMED earned a news sentiment score of 1.5 on InfoTrie's scale. They also assigned press coverage about the medical technology company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days.

Who are some of CONMED's key competitors?

What other stocks do shareholders of CONMED own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CONMED investors own include AT&T (T), Align Technology (ALGN), Gilead Sciences (GILD), Incyte (INCY), Neurocrine Biosciences (NBIX), Amgen (AMGN), Exelixis (EXEL), Fate Therapeutics (FATE), Seattle Genetics (SGEN) and Texas Instruments (TXN).

Who are CONMED's key executives?

CONMED's management team includes the folowing people:
  • Mr. Curt R. Hartman, CEO, Pres & Director (Age 55)
  • Mr. Patrick J. Beyer, Pres of CONMED International (Age 53)
  • Mr. Stanley W. Peters III, VP & GM of U.S. Advanced Surgical (Age 44)
  • Mr. Nathan Folkert, VP & GM of U.S. Orthopedics (Age 44)
  • Mr. Todd W. Garner, Exec. VP & CFO (Age 50)

Who are CONMED's major shareholders?

CONMED's stock is owned by a number of of institutional and retail investors. Top institutional investors include Strs Ohio (0.26%), Los Angeles Capital Management & Equity Research Inc. (0.24%), Virginia Retirement Systems ET AL (0.10%), Mercer Global Advisors Inc. ADV (0.07%), Mercer Global Advisors Inc. ADV (0.04%) and BNP Paribas Arbitrage SA (0.02%). Company insiders that own CONMED stock include Charles Farkas, Daniel Jonas, Dirk Kuyper, Heather L Cohen, Jo Ann Golden, Luke A Pomilio, Nathan Folkert, Peter K Shagory, Stanley W Peters III and Terence M Berge. View Institutional Ownership Trends for CONMED.

Which institutional investors are selling CONMED stock?

CNMD stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio and Versant Capital Management Inc. Company insiders that have sold CONMED company stock in the last year include Daniel Jonas, Dirk Kuyper, Jo Ann Golden, Nathan Folkert, Peter K Shagory, Stanley W Peters III and Terence M Berge. View Insider Buying and Selling for CONMED.

Which institutional investors are buying CONMED stock?

CNMD stock was bought by a variety of institutional investors in the last quarter, including Mercer Global Advisors Inc. ADV, Mercer Global Advisors Inc. ADV, Los Angeles Capital Management & Equity Research Inc., Brinker Capital Inc., Virginia Retirement Systems ET AL, BNP Paribas Arbitrage SA, Wendell David Associates Inc. and Meeder Asset Management Inc.. Company insiders that have bought CONMED stock in the last two years include Charles Farkas and Heather L Cohen. View Insider Buying and Selling for CONMED.

How do I buy shares of CONMED?

Shares of CNMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CONMED's stock price today?

One share of CNMD stock can currently be purchased for approximately $81.32.

How big of a company is CONMED?

CONMED has a market capitalization of $2.30 billion and generates $859.63 million in revenue each year. The medical technology company earns $40.85 million in net income (profit) each year or $2.18 on an earnings per share basis. CONMED employs 3,100 workers across the globe.

What is CONMED's official website?

The official website for CONMED is http://www.conmed.com.

How can I contact CONMED?

CONMED's mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The medical technology company can be reached via phone at 315-797-8375.


MarketBeat Community Rating for CONMED (NASDAQ CNMD)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  331 (Vote Outperform)
Underperform Votes:  265 (Vote Underperform)
Total Votes:  596
MarketBeat's community ratings are surveys of what our community members think about CONMED and other stocks. Vote "Outperform" if you believe CNMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/25/2019 by MarketBeat.com Staff

Featured Article: What is the S&P 500 Index?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel